SWOG clinical trial number
CTSU/E2100

A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Closed
Phase
Published
Abbreviated Title
ADVANCED
Activated
11/01/2002
Closed
05/26/2004
Participants
CTSU

Research committees

Breast Cancer

Treatment

Paclitaxel Bevacizumab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU website (http://www.ctsu.org/) for information.

Publication Information Expand/Collapse

2020

Economic evaluations in NCI-sponsored network cancer clinical trials

VT Nghiem;R Vaidya;GH Lyman;DL Hershman;SD Ramsey;JM Unger Value in Health Dec;23(12):1653-1661. doi: 10.1016/j.jval.2020.08.2095. Epub 2020 Oct 9

PMid: PMID33248521 | PMC number: PMC8262264

2014

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

BP Schneider;L Li;F Shen;KD Miller;M Radovich;A O'Neill;RJ Gray;D Flockhart;G Jiang;Z Wang;D Lai;D Koller;H Pratt;C Dang;D Northfelt;E Perez;T Shenkier;M Cobleigh;ML Smith;E Railey;A Partridge;J Gralow;J Sparano;N Davidson;T Faroud;G Sledge British Journal of Cancer 111(6):1241-1248;

PMid: PMID25117820 | PMC number: PMC4453857

2013

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial

BP Schneider;RJ Gray;M Radovich;F Shen;G Vance;L Li;G Jiang;J Gralow;MN Dickler;M Cobleigh;EA Perez;T Shenkier;K Vang Nielsen;S Muller;A Thor;G Sledge, Jr;JA Sparano;NE Davidson;SS Badve Clinical Cancer Research 19(5):1281-1289

PMid: PMID23340303 | PMC number: PMC3594423

2008

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 [PMC2653128; PMID18824714]

BP Schneider;M Wang;M Radovich;GW Sledge;S Badve;A Thor;D Flockhart;B Hancock;N Davidson;J Gralow;M Dickler;EA Perez;H Cobleigh;T Shenkier;S Edgerton;KD Miller Journal of Clinical Oncology 26(28):4672-4678

2007

Paclitaxel plus bevacixumab versus paclitaxel alone for metastatic breast cancer

K Miller;M Wang;J Gralow;M Dickler;M Cobleigh;E Perez;T Shenkier;D Cella;N Davidson New England Journal of Medicine 357(26):2666-2676

PMid: PMID18160686

2005

A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100)

KD Miller;M Wang;JR Gralow;M Dickler;MA Cobleigh;EA Perez;TN Shenkier;NE Davidson Breast Cancer Research and Treatment 94(Suppl 1):S6(#3)

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase